Skip to main content

YES.  You can complete your Inhalation General Toxicology study.

Have you considered extending your pharmaceutical product’s lifespan using inhaled medicines as a secondary indication? Know that Labcorp has increased inhalation capacity and capability in the U.S. and UK. This enables you to utilize a drug that’s been previously developed for a non-inhaled application—most commonly oral or dermal—and repurpose it to an inhaled form to capitalize on new opportunities for respiratory ailments. Explore the potential now.

Although oral drug administration is the most common type of drug delivery, many patients prefer inhaled medicines, if possible, over injections or other more invasive delivery methods. Inhalation toxicology studies are becoming vital in assessing the safety and potential toxicity of inhaled drugs or chemicals as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) also become more common.

Why You Might Want to Consider the Inhalation Route

    • Ease of use by patients = better adoption and adherence. Inhaled medicines are preferred over injections or other more invasive methods. 
    • Rapid drug absorption. The lung's permeable membrane allows for rapid administration and fast metabolism into the body to treat rapid onset symptoms. 
    • Reduced cost impact on the healthcare system. Both handheld and measured dose inhalers are standard medical technology that both staff and in-home patients are already familiar with, making it a low-barrier and low-cost impact on the healthcare system. 
    • New generation of inhaler devices and techniques. The 3rd generation of devices can now include engineered products, which can potentially reduce the drug volume needed to reach efficacy as well as side effects. 
    • Technological device advancements.New devices have made impressive gains, including electronic feedback, volume monitoring, electrostatic charging, specialized nano-carriers and humidity / temperature compensated delivery.  
    • Device patents can potentially extend product life. You might be able to benefit from the patent on a device even after a pharma patent expires. 

    What to Expect From Our Inhalation Capabilities

    Less test material = more cost savings

    Test material is expensive to manufacture. We've miniaturized toxicology delivery systems to minimize material losses through airflow volumes, designed a set of 3D face masks to prevent leakage and developed techniques to enhance the bioavailability of the test item, requiring a lower dosage.

    Integrated & combo development experience

    As a full-service CRO, you'll have access to efficacy pharmacology models for respiratory, respiratory clinical trials, the device development team for a drug/device combo, and the market access team, skilled at helping you understand the complex pricing strategies for a drug-device combo.

    A dedicated support team

    From our purpose-built inhalation toxicology facility and in-house aerosolization engineering capabilities to our world-renowned scientific staff and dedicated inhalation study directors that oversee more than 150 inhalation studies annually, you and your compound will be well-supported.

    Breathing new life
    NEW INHALATION BUILDOUT

    Breathing new life into inhaled medicines

    The inhaled medicine market is booming with over 100 pharmaceutical compounds in development for the treatment of respiratory ailments. We are responding to this rapid growth with an estimated $10 million expansion. Read all about our investments in inhalation.

    Read now

    REDEFINING WHAT’S POSSIBLE FOR YOUR STUDIES

    Transforming our services in Early Development

    We’ve invested more than $700 million in scientific innovations to advance your nonclinical studies. With our expanded lab space, newest technologies and digitized back offices, the solutions we provide are more innovative than ever.

    Explore our changes
    Breathing new life

    Let's start a conversation